Origin Bio
Generates spatial, molecular, and functional maps of patient tumors to power cancer therapeutic discovery.
Generates spatial, molecular, and functional maps of patient tumors to power cancer therapeutic discovery.
Origin Bio's platform generates spatial, molecular, and functional maps from patient tumor samples, combining wet-lab tissue processing with multimodal AI models. Its Axis model designs and predicts regulatory DNA elements such as enhancers and promoters that can program therapeutic gene expression in target cell states.
The workflow sources FFPE tumor blocks and live tumor resections, applies spatial transcriptomics, morphology imaging, and ex vivo perturbation assays, and feeds the resulting data into models for target discovery and patient stratification.
Demand for safer cell and gene therapies is driving interest in regulatory DNA elements that control where, when, and how strongly therapeutic genes are expressed. Origin Bio's data and models are positioned to support pharmaceutical and AI partners working on cancer and other indications.
The company plans to license its proprietary datasets and sequence designs to biotech and pharmaceutical firms, while also offering research access to its generated sequence libraries through resources such as Switch.
Origin Bio combines patient-derived tissue data with a unified generative and predictive DNA model, Axis, which the company reports outperforms Google DeepMind's AlphaGenome on regulatory element binding benchmarks. By generating and experimentally validating large libraries of regulatory sequences, it can explore a broader design space than motif-repeating or random-ligation approaches.
The platform's ex vivo perturbation capability lets it measure drug and genetic-modifier responses in native tissue, while its multimodal data integration supports both internal therapeutic programs and external licensing partnerships.
